| 9.01 0.1 (1.12%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.8 | 1-year : | 11.29 |
| Resists | First : | 9.24 | Second : | 9.67 |
| Pivot price | 9 |
|||
| Supports | First : | 8.56 | Second : | 7.13 |
| MAs | MA(5) : | 8.99  |
MA(20) : | 8.99 |
| MA(100) : | 8.83 |
MA(250) : | 9.01 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.2 |
D(3) : | 17.9 |
| RSI | RSI(14): 49.9 |
|||
| 52-week | High : | 12.58 | Low : | 6.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ XLO ] has closed below upper band by 48.8%. Bollinger Bands are 75.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.14 - 9.18 | 9.18 - 9.22 |
| Low: | 8.78 - 8.84 | 8.84 - 8.88 |
| Close: | 8.93 - 9.01 | 9.01 - 9.08 |
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Fri, 02 Oct 2026
Xilio Therapeutics, Inc. (XLO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 02 Oct 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mon, 28 Sep 2026
Xilio's new medical chief brings over 20 years in medicine and research - Stock Titan
Mon, 28 Sep 2026
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer - GlobeNewswire
Mon, 28 Sep 2026
A new medical chief gets options to buy 105,000 Xilio shares at $8.91 each. - Stock Titan
Wed, 02 Sep 2026
Xilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 Plan - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 25.9 (%) |
| Held by Institutions | 50.1 (%) |
| Shares Short | 422 (K) |
| Shares Short P.Month | 268 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.78 |
| Profit Margin | -34.1 % |
| Operating Margin | -18.7 % |
| Return on Assets (ttm) | -13.7 % |
| Return on Equity (ttm) | -55.1 % |
| Qtrly Rev. Growth | 131.1 % |
| Gross Profit (p.s.) | 8.1 |
| Sales Per Share | 9.74 |
| EBITDA (p.s.) | -4.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -28.16 |
| PEG Ratio | 0 |
| Price to Book value | 1.15 |
| Price to Sales | 0.92 |
| Price to Cash Flow | -0.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|